These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 18215298)

  • 21. Drug delivery trends in clinical trials and translational medicine.
    Chien JY; Ho RJ
    J Pharm Sci; 2008 Jul; 97(7):2543-7. PubMed ID: 18512222
    [No Abstract]   [Full Text] [Related]  

  • 22. Biosimulation software is changing research.
    Ho RL; Bartsell LT
    Biotechnol Annu Rev; 2004; 10():297-302. PubMed ID: 15504712
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A Historical View and Vision into the Future of the Field of Safety Pharmacology.
    Bass AS; Hombo T; Kasai C; Kinter LB; Valentin JP
    Handb Exp Pharmacol; 2015; 229():3-45. PubMed ID: 26091634
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Strategic applications of toxicogenomics in early drug discovery.
    Ryan TP; Stevens JL; Thomas CE
    Curr Opin Pharmacol; 2008 Oct; 8(5):654-60. PubMed ID: 18760379
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Chemistry-enabled drug delivery (prodrugs): recent progress and challenges.
    Clas SD; Sanchez RI; Nofsinger R
    Drug Discov Today; 2014 Jan; 19(1):79-87. PubMed ID: 23993918
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Exploratory safety pharmacology: a new safety paradigm to de-risk drug candidates prior to selection for regulatory science investigations.
    Cavero I
    Expert Opin Drug Saf; 2009 Nov; 8(6):627-47. PubMed ID: 19998526
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Translational strategies for development of monoclonal antibodies from discovery to the clinic.
    Tabrizi MA; Bornstein GG; Klakamp SL; Drake A; Knight R; Roskos L
    Drug Discov Today; 2009 Mar; 14(5-6):298-305. PubMed ID: 19152840
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Assessment of drug metabolites.
    Izumi T
    Drug Metab Pharmacokinet; 2011; 26(2):121-2. PubMed ID: 21532211
    [No Abstract]   [Full Text] [Related]  

  • 29. The new pre-preclinical paradigm: compound optimization in early and late phase drug discovery.
    Caldwell GW; Ritchie DM; Masucci JA; Hageman W; Yan Z
    Curr Top Med Chem; 2001 Nov; 1(5):353-66. PubMed ID: 11899102
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Perfused human organs versus Mary Shelley's Frankenstein.
    Leung L
    J Transl Med; 2009 Jan; 7():9. PubMed ID: 19166591
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Translational PK/PD modeling for cardiovascular safety assessment of drug candidates: Methods and examples in drug development.
    Caruso A; Frances N; Meille C; Greiter-Wilke A; Hillebrecht A; Lavé T
    J Pharmacol Toxicol Methods; 2014; 70(1):73-85. PubMed ID: 24879942
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Preclinical safety evaluation.
    Holt JD; Nuttall JP
    Curr Top Microbiol Immunol; 2014; 383():55-78. PubMed ID: 23612993
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Optimizing the preclinical/clinical interface: an Informa Life Sciences conference 12-13 December, 2006, London, UK.
    Cavero I
    Expert Opin Drug Saf; 2007 Mar; 6(2):217-24. PubMed ID: 17367268
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Biophysics in drug discovery: impact, challenges and opportunities.
    Renaud JP; Chung CW; Danielson UH; Egner U; Hennig M; Hubbard RE; Nar H
    Nat Rev Drug Discov; 2016 Oct; 15(10):679-98. PubMed ID: 27516170
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Emerging technologies and challenges for better and safer drugs.
    Theodosiou M; Amir-Aslani A; Mégarbane B
    Biotechnol Lett; 2014 Apr; 36(4):677-84. PubMed ID: 24243233
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Chocolate, an effective means of oral drug delivery in rats.
    Huang-Brown KM; Guhad FA
    Lab Anim (NY); 2002 Nov; 31(10):34-6. PubMed ID: 12404013
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A model-based assay design to reproduce in vivo patterns of acute drug-induced toxicity.
    Kuepfer L; Clayton O; Thiel C; Cordes H; Nudischer R; Blank LM; Baier V; Heymans S; Caiment F; Roth A; Fluri DA; Kelm JM; Castell J; Selevsek N; Schlapbach R; Keun H; Hynes J; Sarkans U; Gmuender H; Herwig R; Niederer S; Schuchhardt J; Segall M; Kleinjans J
    Arch Toxicol; 2018 Jan; 92(1):553-555. PubMed ID: 28852801
    [No Abstract]   [Full Text] [Related]  

  • 38. Drug discovery today.
    Schwardt O; Kolb H; Ernst B
    Curr Top Med Chem; 2003; 3(1):1-9. PubMed ID: 12570684
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Application of in silico, in vitro and preclinical pharmacokinetic data for the effective and efficient prediction of human pharmacokinetics.
    Grime KH; Barton P; McGinnity DF
    Mol Pharm; 2013 Apr; 10(4):1191-206. PubMed ID: 23253040
    [TBL] [Abstract][Full Text] [Related]  

  • 40. In vitro testing of drug absorption for drug 'developability' assessment: forming an interface between in vitro preclinical data and clinical outcome.
    Sun D; Yu LX; Hussain MA; Wall DA; Smith RL; Amidon GL
    Curr Opin Drug Discov Devel; 2004 Jan; 7(1):75-85. PubMed ID: 14982151
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.